Not long ago, hallucinogenic mushrooms were more closely associated with 1960s counterculture than with medical protocols. Today, psilocybin—their active substance—is making its way into hospitals and research labs around the world. Controlled clinical trials are exploring its potential to treat mental disorders that often resist traditional approaches. Here’s a look at this therapeutic revolution in the making.
Psilocybin and the Brain: A Rewiring of Neural Circuits
Psilocybin primarily acts on serotonin receptors, especially 5-HT2A, inducing altered states of consciousness. These states foster increased brain plasticity, allowing for a reorganization of neural circuits. This reconfiguration may explain the significant improvements observed in various psychiatric conditions.
Several countries are currently conducting clinical studies or offering regulated use:
Australia: Since July 2023, psychiatrists can prescribe psilocybin to treat treatment-resistant depression.
Switzerland: Psilocybin-assisted therapy is available in clinical settings under strict supervision.
Netherlands: Psychedelic retreats offer guided therapeutic experiences, though their medical status remains ambiguous.
United States, Canada, France, United Kingdom: Ongoing clinical trials are evaluating the effectiveness of psilocybin across multiple mental health disorders.
Treatment-Resistant Depression: Promising Results
Treatment-resistant depression poses a major challenge in psychiatry. Studies at Johns Hopkins University have shown that psilocybin-assisted therapy can lead to a significant reduction in depressive symptoms, with effects lasting up to a year after just one session.
In France, the COMP006 study, led by Dr. Lucie Berkovitch at Sainte-Anne Hospital in Paris, is evaluating psilocybin’s effectiveness for patients with resistant depression. Participants receive a single dose of psilocybin, along with therapeutic support before, during, and after the session.
Alcoholism: Toward Reduced Relapse Rates
Alcohol dependence is notoriously difficult to treat, with high relapse rates. Clinical trials are exploring how psilocybin might support sustained abstinence. At the Nîmes University Hospital in France, a pilot study is evaluating its impact on patients with alcohol use disorder.
In Belgium, the Brugmann University Hospital in Brussels has launched a similar trial—the first of its kind in the country.
In the U.S., a study by NYU Langone’s Center for Psychedelic Medicine found that 48% of participants who received psilocybin remained abstinent from alcohol eight months after treatment.
OCD, Anorexia, and PTSD: Early-Stage Explorations
Obsessive-Compulsive Disorder (OCD): Early research suggests that psilocybin may reduce OCD symptoms. One study reported a 25% decrease in obsessive thoughts in participants after treatment.
Anorexia Nervosa: One of the most treatment-resistant psychiatric conditions, anorexia is also being studied. A pilot trial at the University of California, San Diego, showed that psilocybin was well tolerated and may help patients shift their body image and eating behaviors.
Post-Traumatic Stress Disorder (PTSD): While MDMA is the most studied psychedelic for PTSD, psilocybin is also being investigated. Ongoing trials are examining its effectiveness in reducing trauma symptoms.
The Dawn of a New Psychiatry?
Research into psychedelics—especially psilocybin—for mental health is accelerating at an unprecedented pace. While early findings are promising, more studies are needed to confirm efficacy and establish standardized treatment protocols.
Integrating these therapies into mainstream psychiatry will also require regulatory reform and proper clinician training.




